Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.

Vivek Subbiah Irene BranaAlessandra LonghiValentina Boni Jean-Pierre Delord Ahmad Awada Pascaline Boudou-RouquetteJohn SarantopoulosGeoffrey I Shapiro Anthony D Elias Ravin RatanCristian FernandezCarmen KahattMartin Cullell-YoungMariano SigueroAli ZeaiterSant P Chawla

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Lurbinectedin was active in the treatment of relapsed Ewing sarcoma and had a manageable safety profile. Lurbinectedin could represent a valuable addition to therapies for Ewing sarcoma, and is currently being evaluated in combination with irinotecan in advanced Ewing sarcoma in a phase Ib/II trial.

Keyphrases

phase ii study
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
multiple myeloma
open label
clinical trial
randomized controlled trial
study protocol
phase iii
phase ii
radiation therapy